#SFHS2609136VPrice Notice for ONIVYDE Pharmaceutical Specialty
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
🇬🇧 English
This notice sets the reimbursement tariff and maximum pre-tax sale price for the hospital medicine ONIVYDE 4.3 mg/ml at €963.690 per UCD, affecting Servier and healthcare institutions that buy or bill this product.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Sets the reimbursement tariff for ONIVYDE 4.3 mg/ml at €963.690 per UCD
- Sets the maximum pre-tax sale price to healthcare institutions at €963.690 per UCD
- Applies to the Servier-operated pharmaceutical specialty listed in the notice
Obligations
What this law requires
medium
Apply a reimbursement tariff of €963.690 excluding tax per UCD for ONIVYDE 4.3 mg/ml perfusion vial 10 ml, UCD code 3400894264910.
healthcare institutions billing reimbursable hospital medicineshealth insurance reimbursement processors
operational
medium
Do not sell ONIVYDE 4.3 mg/ml perfusion vial 10 ml, UCD code 3400894264910, to healthcare establishments above the maximum pre-tax sale price of €963.690 per UCD.
pharmaceutical laboratory marketing the producthospital medicine suppliers
prohibition
Affected Parties
Les Laboratoires ServierHealthcare institutions purchasing or billing ONIVYDE+1 more…
Tags
pharmaceutical pricing,hospital medicines,reimbursement